Artelo Biosciences Inc. (ARTL)
$6.04
$-0.18
(-2.89%)
As on 04-Sep-2026 16:00EDT
Market cap
$3 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-7.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.2
-
Debt to Equity
0
-
Book Value
$10.7
-
EPS
$-71.9
-
Face value
--
-
Shares outstanding
547,774
10 Years Aggregate
CFO
$-31.17 Mln
EBITDA
$-39.37 Mln
Net Profit
$-36.86 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
| -81.7 | -9.6 | -54.0 | -97.4 | -72.9 | -69.3 | -- |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
| -80.8 | -24.1 | -51.6 | -62.9 | -28.9 | -73.0 | -70.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Artelo Biosciences (ARTL)
|
6.0 | 3.3 | 0.0 | -12.7 | -- | -- | -- | 0.7 |
| 86.3 | 12,161.6 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.2 | |
| 270.6 | 17,746.8 | 1,054.4 | 755.9 | 5.7 | -- | 20.9 | 10.5 | |
| 72.7 | 10,109.8 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.5 | |
| 59.0 | 14,621.6 | 2,435.9 | 860.6 | 31.0 | 43 | 18.6 | 7.9 | |
| 110.2 | 12,506.3 | 1,663.7 | 413.6 | 36.3 | 430 | 32.3 | 86.7 | |
| 358.2 | 10,603.5 | 440.5 | 241.5 | 33.4 | 18.7 | 44.9 | 8.1 | |
| 117.4 | 9,761.1 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.5 | |
| 541.1 | 12,501.2 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 23.9 | |
| 591.3 | 16,503.9 | 2,782.3 | 491.5 | 21.1 | 110.1 | 34.7 | 38.2 |
Shareholding Pattern
View DetailsAbout Artelo Biosciences (ARTL)
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual... cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of cancer-related anorexia; and ART12.11, a cocrystal composition of cannabidiol and tetramethylpyrazine for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California. Read more
-
President, CEO, CFO, Treasurer, Secretary & Director
Mr. Gregory D. Gorgas M.B.A.
-
President, CEO, CFO, Treasurer, Secretary & Director
Mr. Gregory D. Gorgas M.B.A.
-
Headquarters
Solana Beach, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Artelo Biosciences (ARTL)
What is the current share price of Artelo Biosciences Inc (ARTL) Today?
The share price of Artelo Biosciences Inc (ARTL) is $6.04 (NASDAQ) as of 04-Sep-2026 16:00 EDT. Artelo Biosciences Inc (ARTL) has given a return of -72.88% in the last 3 years.
What is the current PB & PE ratio of Artelo Biosciences Inc (ARTL)?
Since, TTM earnings of Artelo Biosciences Inc (ARTL) is negative, P/E ratio is not available.
The P/B ratio of Artelo Biosciences Inc (ARTL) is 0.69 times as on 04-Sep-2026, a 87 discount to its peers’ median range of 5.33 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.02 |
-0.25 |
2024 |
-0.17 |
0.60 |
2023 |
-0.24 |
0.19 |
2023 |
-- |
-- |
2022 |
-0.41 |
0.21 |
What is the 52 Week High and Low of Artelo Biosciences Inc (ARTL)?
The 52-week high and low of Artelo Biosciences Inc (ARTL) are Rs 179.19 and Rs 4.68 as of 07-Sep-2026.
What is the market cap of Artelo Biosciences Inc (ARTL)?
Artelo Biosciences Inc (ARTL) has a market capitalisation of $ 3 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Artelo Biosciences Inc (ARTL)?
Before investing in Artelo Biosciences Inc (ARTL), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.